CN115197322B - 用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用 - Google Patents
用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用 Download PDFInfo
- Publication number
- CN115197322B CN115197322B CN202210860021.5A CN202210860021A CN115197322B CN 115197322 B CN115197322 B CN 115197322B CN 202210860021 A CN202210860021 A CN 202210860021A CN 115197322 B CN115197322 B CN 115197322B
- Authority
- CN
- China
- Prior art keywords
- antibodies
- cells
- cll
- mrd
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 title claims abstract description 57
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 title claims abstract description 38
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 58
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 30
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 30
- 238000001514 detection method Methods 0.000 claims description 30
- 210000000265 leukocyte Anatomy 0.000 claims description 22
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 18
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 17
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 17
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 17
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 15
- 102100039564 Leukosialin Human genes 0.000 claims description 15
- 102100027221 CD81 antigen Human genes 0.000 claims description 9
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 8
- 230000001464 adherent effect Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 6
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 6
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000006641 stabilisation Effects 0.000 claims description 5
- 238000011105 stabilization Methods 0.000 claims description 5
- 108010006464 Hemolysin Proteins Proteins 0.000 claims description 4
- 238000010586 diagram Methods 0.000 claims description 4
- 239000003228 hemolysin Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000007850 fluorescent dye Substances 0.000 abstract description 2
- 238000013394 immunophenotyping Methods 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种用于慢性淋巴细胞白血病免疫分型治疗后微小残留病灶检测的抗体组合物及其应用,抗体组合物包括一组8种抗体组合。本发明优化抗体组合和对应抗体的荧光标记组合以及结果判读方法,只需要使用一管8种抗体一次上样,既可以全面、高效的对CLL治疗后微小残留病灶(MRD)进行检测,判断CLL的预后和治疗效果,具有极高的敏感性和特异性。
Description
技术领域
本发明涉及抗体医药领域,尤其是涉及一种用于慢性淋巴细胞白血病免疫分型治疗后微小残留病灶检测的抗体组合物及其应用。
背景技术
慢性淋巴细胞白血病(CLL)是一种具有特征性免疫表型的高度异质性的成熟小B细胞淋巴瘤/白血病。近年来,随着新型靶向药物的不断研发和临床使用,CLL的疗效及预后取得了极大改善,但患者体内存在的微小残留病灶(MRD)仍然是导致疾病复发的根源。因此,临床需要灵敏精准且易于推广的MRD检测手段作为CLL疗效评估的重要指标。由于多参数流式细胞术(MFC)具有快速、经济、结果可靠、可以准确定量以及适用于几乎所有CLL患者的优点,已经成为目前CLL最常用的MRD检测方法。为了最大程度获取精确的结果且避免多余抗体导致的仪器补偿难以调节以及结果难以判断,抗体组合应尽可能满足获取足够的信息量且不冗余。
目前,国际尚无标准化检测方案,临床上完成上述检测目主要参考欧洲慢性淋巴细胞白血病研究中心(ERIC)发布的方案。2007年和2012年ERIC分别发布四色四管方案(Kappa/lambda/CD5/CD19、CD20/CD38/CD5/CD19、CD81/CD22/CD19/CD5和CD79b/CD43/CD19/CD5)和六色两管方案(CD19/CD5/CD20/+CD3/CD38/CD79b和CD19/CD5/CD20/+CD81/CD22/CD43),而在2016年ERIC发布8色单管抗体组合方案(CD81/CD20/CD22/CD43/CD5/CD79b/CD19/CD3),认为8色单管抗体组合方案相较多管四色和六色的多管组合,在CLL的MRD检测中体现出更好的敏感性和特异性,其优势在于不仅能一次获得更多抗原间的表达信息,而且能有效降低多管检测造成的细胞分布不均所导致的结果偏差,检测后首先通过前向散射光(FSC)和侧向散射光(SSC)进行双参数设门圈出所有细胞,再利用CLL典型的免疫表型特点找出残留CLL肿瘤细胞(即CD20(-/dim)CD22(dim)CD79b(dim)CD5+CD19+CD43+CD81-CD3-),用CLL残留肿瘤细胞数除以所有细胞数即为CLL-MRD。
在随后的临床应用中,发现该组合依然存在缺陷,一方面CD22和CD79b在CLL中表达特点一致,均为弱表达,因此同时选择两种明显冗余;另一方面,CD3加入的目的是为了去除和B细胞发生粘黏的T淋巴细胞,但利用CD81/CD43两个标记可去除T细胞(T细胞高表达CD43和CD81,CLL肿瘤细胞表达CD43但不表达CD81),因此CD3也非CLL-MRD检测的必要抗体。
目前存在的问题是:(1)样本储存时间长短、处理制备过程和细胞碎片均会影响最终结果计算,如果仅凭FSC/SCS散射光特点设门圈出有核细胞作为计算MRD的分母,很难保证结果的准确性和一致性,这在多中心临床药物试验比对的结果差异尤为突出。(2)少部分CLL免疫表型不典型,例如肿瘤细胞可以不表达CD5和CD43,也可以强表达CD20和CD79b,这导致ERIC方案无法完全适用于这部分患者的MRD检测。
因此,目前迫切需要设计一种在常用的流式细胞仪上能应用和推广的抗体组合物解决上述技术问题。该组合物应尽可能减少室间和室内差异且同时对典型和不典型免疫表型CLL进行精准检测。
发明内容
本发明目的在于针对现有技术的缺陷,提供一种在临床常规使用的流式细胞仪上检测的慢性淋巴细胞白血病的抗体组合物,具体包括一管8色抗体的组合物,主要用慢性淋巴细胞白血病微小残留病的精准检测。并提供上述抗体组合物应用。
为实现上述目的,本发明采用以下技术方案:一种用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物,由以下抗体组成:抗CD19抗体、抗CD5抗体、抗CD20抗体、抗CD45抗体、抗CD79b抗体、抗ROR1抗体、抗CD43抗体和抗CD 81抗体。
进一步的,抗体标记不同的荧光标记。
进一步的,荧光标记按照抗体抗CD81、抗CD43、抗CD79b、抗CD5、抗CD19、抗CD20、抗ROR1、抗CD45的顺序分别为:FITC、PE、PerCP-Cy5.5、PE-Cy7、APC、APC-A750、BV421和KO。
一种用于流式细胞术检测慢性淋巴细胞白血病微小残留病灶的试剂盒,包括上述任一所述的抗体组合物。
进一步的,试剂盒还包括上述所述的荧光标记。
进一步的,试剂盒还包括:红细胞裂解液。
一种上述任一所述抗体组合物在制备用于检测慢性淋巴细胞白血病微小残留病灶的试剂盒中的应用。
进一步的,检测慢性淋巴细胞白血病微小残留病灶的过程包括以下步骤:
(1)将待测样本加入到流式管中,将细胞浓度调整为5~10x106/mL;所述待测样本为外周血或骨髓液;
(2)在流式管中加入权利要求1至3任一所述的已被相应荧光素标记的抗体组合物充分混匀,室温避光孵育15min;
(3)向步骤(2)孵育后的流式管中加入1×FACS溶血素,混匀后室温避光静置8~10min;300g离心洗涤5min,弃去上清;
(4)向步骤(3)的流式管中加入PBS洗液,300g离心洗涤5min,弃去上清。加入PBS重悬细胞;
(5)对步骤(4)中的重悬细胞进行流式细胞上机检测,利用Time/CD45、FSC INT/FSC PEAK和/或FSC INT/SSC INT散点图,圈出液流稳定区间、去除黏连体和细胞碎片;通过CD45联合SSC圈出所有白细胞群,在所有白细胞门中通过CD45/SSC设门圈出淋巴细胞,圈出CD19+B淋巴细胞;通过CD5/CD19双参数图圈出CD5+CD19+细胞;利用CD20/CD79b圈出CD20(-/dim)CD79b(dim)CD5+CD19+细胞;通过CD43/CD81设门圈出CD20(-/dim)CD79b(dim)CD5+CD19+CD43(strong+)CD81-细胞群;通过ROR1/CD19设门圈出ROR1+CD19+细胞群,即为CLL-MRD细胞,用图中最终确定的CLL细胞数除以白细胞总数,即CLL-MRD占白细胞百分比。
一种用于检测慢性淋巴细胞白血病微小残留病灶的装置,包括:检测单元和分析单元;所述检测单元包括用于通过流式细胞术检测来自待测个体的样本的试剂材料,用于获得样本的检测结果;所述试剂材料包括上述任一项所述的抗体组合物;
所述分析单元用于分析检测单元的检测结果。
进一步的,所述通过流式细胞术检测来自待测个体的样本的过程包括:利用权利要求1至3任一项所述的抗体组合物对待测样本进行处理后制备流式细胞上机样品;进行流式细胞上机检测;其中流式细胞上机检测时按照以下方式设门:利用Time/CD45、FSC INT/FSC PEAK和/或FSC INT/SSC INT散点图,圈出液流稳定区间、去除黏连体和细胞碎片;通过CD45(人类白细胞共同抗原)联合侧向散射光SSC圈出所有白细胞群;在所有白细胞门中通过CD45/SSC设门圈出淋巴细胞;圈出CD19+B淋巴细胞;通过CD5/CD19双参数图圈出CD5+CD19+细胞;利用CD20/CD79b圈出CD20(-/dim)CD79b(dim)CD5+CD19+细胞;通过CD43/CD81设门圈出CD20(-/dim)CD79b(dim)CD5+CD19+CD43(strong+)CD81-细胞群;通过ROR1/CD19设门圈出ROR1+CD19+细胞群;
所述分析单元分析检测单元的检测结果时,将圈出的ROR1+CD19+细胞群设为CLL-MRD细胞,用图中最终确定的CLL-MRD细胞数除以白细胞总数,即MRD占白细胞百分比。
8种抗体组合物的抗体种类及配伍的荧光素见表1。抗体均为单克隆抗体。
表1
本发明具有以下有益效果:利用一组单管抗体组合,用于CLL-MRD的检测。与目前临床普遍采用4-6色抗体组合对CLL-MRD进行传统流式细胞仪免疫分型检测,每种疾病均需要检测多管抗体组合,本发明仅使用1管抗体组合(8个抗体),并对抗体组合物进行了优化,建立了数据采集和分析流程,可对CLL-MRD进行精准检测。因此,本发明不仅减少了对标本量的需求及操作数量,节省了操作时间,同时减少了设门抗体的重复应用,增加了有效抗体的使用数量,能同时观察8种抗体是否同时表达,分析所述抗体相互组合的表型关系,增加对CLL-MRD检测的准确性、特异性和敏感性。本发明首创利用Time/CD45、FSC INT/PEAK和FSC INT/SSC INT散点图,圈出液流稳定区间细胞,能首先有效去除黏连体和细胞碎片。本发明公开了使用新的CLL特异性标记物ROR1联合经典核心抗体进行MRD分析方法,该标记物在CLL肿瘤细胞中普偏高表达,包括在不典型免疫表型的CLL中。另外,本发明采用CD45联合侧向散射光SSC设门圈取白细胞作为计算分母,有效降低了以往采用散射光信号FSC联合SSC设门作为计算分母无法导致的室内和室间差异的产生。
附图说明
图1是实施例1CLL患者采用MFC检测MRD分析流程图。
图2是实施例2采用FSC/SSC和CD45/SSC设门后的结果差异图。
图3是实施例3MRD检测结果(显示一例CLL患者治疗后所送外周血样本分别在24小时(A)、48小时(B)和72小时(C)几个时间点采用本发明技术进行MRD检测,结果具有高度一致性)。
图4是对比例1采用ERIC方案进行MRD检测结果(显示一例CLL患者治疗后所送外周血样本分别在24小时(A)、48小时(B)和72小时(C)几个时间点采用ERIC方案进行MRD检测,结果显示较大的差异性)。
图4是对比例1采用ERIC方案进行MRD检测结果(显示一例CLL患者治疗后所送外周血样本分别在24小时(A)、48小时(B)和72小时(C)几个时间点采用ERIC方案进行MRD检测,结果显示较大的差异性)。
具体实施方式
为了使本技术领域的人员更好地理解本申请方案,下面将结合本申请实施例中的附图,对本申请实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本申请一部分的实施例,而不是全部的实施例。基于本申请中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本申请保护的范围。
需要说明的是,本申请的说明书和权利要求书及上述附图中的术语“包括”和“具有”以及他们的任何变形,意图在于覆盖不排他的包含,例如,包含了一系列步骤或单元的过程、方法、系统、产品或设备不必限于清楚地列出的那些步骤或单元,而是可包括没有清楚地列出的或对于这些过程、方法、产品或设备固有的其它步骤或单元。
以下实施例用于说明本发明,但不用来限制本发明的范围。若未特别指明,实施例说明书中所用的技术手段为本领域技术人员所熟知的常规手段。下述实施例所使用的实验方法如无特殊说明,均为常规方法。下述实施例中所有的材料、试剂等,如无特殊说明,均可从商业途径获得。
本发明采用流式细胞术对临床CLL患者的骨髓和外周血标本进行免疫表型分析。
试剂的配制
一种CLL-MRD检测适应症的抗体组合:按照表1中的组合配置抗体组合。将上述抗体按照配比方式分别混合装于1个容器内,用于确定CLL的所有标本MRD的免疫表型标记。上述抗体均可直接商业购买获得,抗体均为单克隆抗体。本发明实施例的抗体从BD公司,Biolegend、贝克曼公司购买。8种抗体组合物的抗体种类、荧光素及容量配伍见表1。
表1
将上述抗体组合分别制备CLL-MRD检测试剂盒。
试剂盒还包括红细胞溶解液,红细胞溶解液可以自行配置也可以商业购买(如BD公司)。8种抗体组合流式细胞术检测CLL-MRD。
一、实验主要材料及仪器
1.材料:10×PBS缓冲液(实验室自配)、流式细胞仪专用溶血素(BD公司);
2.仪器:Navios型号10色流式细胞仪,配备405nm,488nm、635nm三根激光,10个荧光检测器。台式低速离心机、漩涡混匀器。
二、方法
1.样本采集:
将取材到的人外周血或骨髓液1~2mL立即置于肝素抗凝管并迅速颠倒数次以防止标本凝固,采集后应尽快送往实验室,常温保存,必须在48小时内检测完成流式细胞术(FCM)检测,按说明书操作。
2.样本制备过程:
(1)细胞计数:计数每微升白细胞数,根据检测结果,将细胞浓度调整为5~10x106/100mL,取200~400μL细胞液加入流式管中。
(2)抗原染色:
a)每管分别加入表1中相应荧光素标记的单克隆抗体预混液和标本充分混匀,室温避光孵育15min;
b)溶血:加入1×FACS溶血素2mL,低速涡流混匀,室温避光静置8~10min。300g离心洗涤5min,弃去上清。
c)洗涤:加入1mL含有0.1%NaN3和1%~2%BSA的PBS洗液,300g离心洗涤5min,弃去上清。加入PBS 200μL悬浮细胞,待上机检测。如不能及时上机检测,则加入0.5mL 1%多聚甲醛,混匀后置于4℃冰箱内保存,24小时内完成检测。
(3)上机检测和数据分析:
a)确定最适电压和补偿:按照流式细胞仪的常规操作方法设定电压和补偿。
b)上机检测和数据采集。
按照设定好的仪器条件,每管获取CD45阳性的白细胞至少20万个,使用Kluza软件分析数据。
实施例1
图1显示一例CLL患者MRD分析方法和检测结果。
图1中A-C分别是利用Time/CD45、FSC INT/PEAK和FSC INT/SSC INT散点图,圈出液流稳定区间、去除黏连体和细胞碎片;D:通过人类白血病共同抗原CD45联合SS圈出所有白细胞群;E:在所有白细胞门中通过CD45/SSC设门圈出淋巴细胞;F:圈出CD19+B淋巴细胞;G-H:通过CD5/CD19双参数图圈出CD5+CD19+细胞和CD5-CD19+细胞;I:利用CD20/CD79b圈出CD20(-/dim)CD79b(dim)CD5+CD19+细胞群;J:通过CD43/CD81设门圈出CD20(-/dim)CD79b(dim)CD5+CD19+CD43(strong+)CD81-细胞群;K:通过ROR1/CD19设门圈出ROR1+CD19+细胞群,即为CLL-MRD细胞,计算MRD结果用“K”图中最终确定的CLL细胞数(1215个)除以“D”图中的白细胞总数(399847万个),即MRD占白细胞的0.3%。
实施例2
图2显示一例CLL患者治疗后所送骨髓样本因溶血不佳或聚集细胞高,对比ERIC的FSC/SSC设门策略和本发明的CD45/SSC设门策略分析的结果差异。左图:采用FSC/SSC设门策略仅能去除细胞碎片,无法去除混在淋巴细胞群中的聚集粘连细胞,导致最终结果计算误差产生;右图:采用FSC/SSC设门去除细胞碎片后再采用CD45/SSC有效将白细胞与死亡以及聚集粘连细胞分离,通过圈取CD45阳性的白细胞群作为计算分母,能有效避免室间差异和室内差异的产生,确保最终计算结果的精确性和一致性。
实施例3
图3显示一例CLL患者治疗后所送外周血样本分别在24小时(A)、48小时(B)和72小时(C)几个时间点采用本发明进行MRD检测,结果具有高度一致性。计算均采用“K”图中最终确定的CLL细胞数除以“D”图中的白细胞总数,即MRD占白细胞百分比。上图MRD=6370/483482=1.31%,中图MRD=6499/504065=1.30%,下图MRD=4816/371435=1.30%。
对比例1
图4显示一例CLL患者治疗后所送外周血样本分别在24小时(A)、48小时(B)和72小时(C)几个时间点采用ERIC方案进行MRD检测,结果显示较大的差异性。计算均采用“J”图中最终确定的CLL细胞数除以“C”图中的细胞总数,即MRD占所有细胞百分比。图A中MRD=157/234604=0.07%,B中MRD=47/139909=0.03%,C中MRD=16/225766=0.007%。
以上所述仅为本发明的优选实施例,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围。
Claims (1)
1.一种检测慢性淋巴细胞白血病微小残留病灶的方法,其特征在于,所述方法步骤如下:
(1)将待测样本加入到流式管中,将细胞浓度调整为5~10x106/mL;所述待测样本为外周血或骨髓液;
(2)在流式管中加入已被相应荧光素标记的抗体组合物充分混匀,室温避光孵育15min;
(3)向步骤(2)孵育后的流式管中加入1× FACS溶血素,混匀后室温避光静置8~10min;300g离心洗涤5min,弃去上清;
(4)向步骤(3)的流式管中加入PBS洗液,300g离心洗涤5min,弃去上清,加入PBS重悬细胞;
(5)对步骤(4)中的重悬细胞进行流式细胞上机检测,利用Time/CD45、FSC INT/FSCPEAK和/或FSC INT/SSC INT散点图,圈出液流稳定区间、去除黏连体和细胞碎片;通过CD45联合SSC圈出所有白细胞群,在所有白细胞门中通过CD45/SSC设门圈出淋巴细胞,圈出CD19+B淋巴细胞;通过CD5/CD19双参数图圈出CD5+CD19+细胞;利用CD20/CD79b圈出CD20(-/dim)CD79b(dim) CD5+CD19+细胞; 通过CD43/CD81设门圈出CD20(-/dim)CD79b(dim) CD5+CD19+CD43(strong+)CD81- 细胞群;通过ROR1/CD19设门圈出ROR1+CD19+ 细胞群,即为CLL-MRD细胞;用图中最终确定的CLL细胞数除以白细胞总数,即CLL-MRD占白细胞百分比;
所述抗体组合物由下述抗体组成:抗CD19抗体、抗CD5抗体、抗CD20抗体、抗CD45抗体、抗CD79b抗体、抗ROR1抗体、抗CD43抗体和抗CD81抗体;
上述方法为非疾病的诊断和治疗方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210860021.5A CN115197322B (zh) | 2022-07-21 | 2022-07-21 | 用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210860021.5A CN115197322B (zh) | 2022-07-21 | 2022-07-21 | 用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115197322A CN115197322A (zh) | 2022-10-18 |
CN115197322B true CN115197322B (zh) | 2024-01-30 |
Family
ID=83584227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210860021.5A Active CN115197322B (zh) | 2022-07-21 | 2022-07-21 | 用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115197322B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107422122A (zh) * | 2012-06-14 | 2017-12-01 | 鹿特丹伊拉斯姆斯大学医疗中心 | 用于检测微小残留病的方法、试剂以及试剂盒 |
CN108458964A (zh) * | 2017-10-31 | 2018-08-28 | 天津协和华美医学诊断技术有限公司 | 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用 |
CN109655616A (zh) * | 2018-12-19 | 2019-04-19 | 广州金域医学检验中心有限公司 | 检测急性髓系白血病细胞的组合试剂及系统 |
CN114460311A (zh) * | 2022-04-13 | 2022-05-10 | 北京大学人民医院 | 用于b-all/lbl免疫分型的试剂组合物及其应用 |
-
2022
- 2022-07-21 CN CN202210860021.5A patent/CN115197322B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107422122A (zh) * | 2012-06-14 | 2017-12-01 | 鹿特丹伊拉斯姆斯大学医疗中心 | 用于检测微小残留病的方法、试剂以及试剂盒 |
CN108458964A (zh) * | 2017-10-31 | 2018-08-28 | 天津协和华美医学诊断技术有限公司 | 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用 |
CN109655616A (zh) * | 2018-12-19 | 2019-04-19 | 广州金域医学检验中心有限公司 | 检测急性髓系白血病细胞的组合试剂及系统 |
CN114460311A (zh) * | 2022-04-13 | 2022-05-10 | 北京大学人民医院 | 用于b-all/lbl免疫分型的试剂组合物及其应用 |
Non-Patent Citations (2)
Title |
---|
Michaela Patz et.al.ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL).《Blood》.2016,第128卷(第128期),第3197-3198页. * |
ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL);Michaela Patz et.al;Blood;第128卷(第128期);第 3197-319 8 页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115197322A (zh) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113777327B (zh) | 用于白血病/淋巴瘤免疫分型初筛的抗体组合物及其应用 | |
Barnett et al. | Guideline for the flow cytometric enumeration of cd34+ haematopoietic stem cellsprepared by the cd34+ haematopoietic stem cell working party | |
Kimoto et al. | Further development of the rat Pig‐a mutation assay: Measuring rat Pig‐a mutant bone marrow erythroids and a high throughput assay for mutant peripheral blood reticulocytes | |
Orfao et al. | Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. | |
JPH0379666B2 (zh) | ||
JPH08506421A (ja) | 細胞関連分子を検出し、その量を測定するための方法および器具 | |
US20210389225A1 (en) | A flow cytometric detection method for lymphocyte in immune cells | |
CN111527406A (zh) | 一种用于流式细胞仪分析的淋巴细胞样品的制备方法 | |
CN114213540B (zh) | 一组用于髓系肿瘤免疫分型的抗体组合物及其应用 | |
JP2001091513A (ja) | 白血球の分類計数方法 | |
Dzik | Principles of counting low numbers of leukocytes in leukoreduced blood components | |
CN115856302A (zh) | 一种用于成熟b细胞肿瘤免疫分型的抗体组合物、试剂盒及其应用和系统 | |
CN112098646B (zh) | 一种定量检测淋巴细胞亚群的试剂盒及其检测方法 | |
CN116482370B (zh) | 一种用于流式细胞筛查浆细胞肿瘤治疗靶点和/或异常表型的抗体组合及其应用 | |
CN104459135B (zh) | 检测样本阴阳性的设备、方法及判断标准的确定方法 | |
Chen et al. | Immunophenotyping by multiparameter flow cytometry | |
Hübl et al. | Measurement of absolute concentration and viability of CD34+ cells in cord blood and cord blood products using fluorescent beads and cyanine nucleic acid dyes | |
JP4279900B2 (ja) | 細胞生存率、有核赤血球、および白血球分類の同時分析方法 | |
CN115197322B (zh) | 用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用 | |
CN115290875A (zh) | 一种6色tbnk淋巴细胞亚群检测试剂盒和检测方法 | |
CN111528219B (zh) | 一种用于t淋巴细胞亚群计数标准物质的冻干保护剂及其应用 | |
Latger‐Cannard et al. | A standardized procedure for quantitation of CD11b on polymorphonuclear neutrophil by flow cytometry: potential application in infectious diseases | |
US7358059B2 (en) | Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement | |
Arroyo et al. | Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision‐making process | |
JP6883826B2 (ja) | 骨髄異形成症候群の診断方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |